Impact of COVID-19 Pandemic on Care of Pulmonary Hypertension Patients

Zhou, Chuan; Sahay, Sandeep; Shlobin, Oksana A.; Levine, Deborah J.; Poms, A.; Soto, Francisco J.; Melendres‐Groves, Lana; Mullin, Christopher J.; Bossone, E.; Balasubramanian, Vijay; Memon, Humna; Kay, Denise; Mathai, S.C.; Highland, K.B.; Elwing, Jean M.

doi:10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a5421

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…7 The findings of our study quantifying the impact of care disruptions associated with the COVID-19 pandemic are supported by the results of a survey related to the care of patients with PH completed by 95 healthcare professionals in the US Pulmonary Vascular Disease NetWork, with responses collected from November 2020 to February 2021. 11 During the pandemic, 84% of physicians used telemedicine for PH patient care (vs. 15% before the pandemic). The survey identified that access to PAHrelated tests was a major area of disruption (>90% of respondents) and around one-third of respondents experienced disruptions with renewal/approval of medications.…”

Section: Discussionmentioning

confidence: 99%

Impact of the COVID‐19 pandemic on care disruptions, outcomes, and costs in patients receiving pulmonary arterial hypertension‐specific therapy in the United States of America: An observational study

George,

Germack,

Goyal

et al. 2023

Pulm. circ.

View full text Add to dashboard Cite

Regular expert follow‐up, risk assessment, and early therapeutic intervention minimize worsening of pulmonary arterial hypertension (PAH). COVID‐19 lockdown measures were challenging for chronic disease management. This retrospective, longitudinal analysis used US claims data (January 12, 2016 to September 11, 2021) for patients treated with PAH‐specific medication to compare in‐person outpatient and specialist visits, telemedicine visits, and PAH‐related tests during 6‐month assessment periods pre‐ and immediately post‐COVID‐19. Hospitalizations, costs, and outcomes were compared in patients with and without care disruptions (no in‐person or telemedicine outpatient visits in immediate post‐COVID‐19 period). Patients in the immediate post‐COVID‐19 (N = 599) versus the pre‐COVID‐19 period (N = 598) had fewer in‐person outpatient visits (mean 1.27 vs. 2.12) and in‐person specialist visits (pulmonologist, 22.9% vs. 37.0% of patients; cardiologist, 27.5% vs. 33.8%); and more telemedicine visits (mean 0.45 vs. 0.02). In the immediate post‐COVID‐19 period, patients were less likely to have a PAH‐related test versus the pre‐COVID‐19 period (incidence rate ratio: 0.700; 95% confidence interval: 0.615−0.797), including electrocardiograms (41.7% vs. 54.2%) and 6‐minute walk distance tests (16.2% vs. 24.9%). In the immediate post‐COVID‐19 period, 48 patients had care disruptions and, in the following year, required more hospital days than those without care disruptions (N = 240) (median 10 vs. 5 days in total) and had higher overall hospitalization costs (median US$34,755 vs. US$20,090). Our findings support the need for minimizing care disruptions to potentially avoid incremental post‐disruption healthcare utilization and costs among patients with serious chronic diseases such as PAH.

show abstract

Section: Discussionmentioning

confidence: 99%

Impact of the COVID‐19 pandemic on care disruptions, outcomes, and costs in patients receiving pulmonary arterial hypertension‐specific therapy in the United States of America: An observational study

George,

Germack,

Goyal

et al. 2023

Pulm. circ.

View full text Add to dashboard Cite

show abstract

“…The ACCP PVD Network steering committee found that 93% of patient care was affected and telemedicine use increased from 15% prepandemic to 84% during the early pandemic. 46 The benefits of telemedicine include increased frequency of monitoring, decreased emergency room visits, reduced hospitalizations, decreased financial costs related to travel, and insight into patients' living environments and surroundings. 47 Limitations include clinician scarcity, legal complexity, and licensure challenges beyond state lines.…”

Section: Telemedicine Tools: What Are They and How To Best Utilize Th...mentioning

confidence: 99%

Pulmonary Hypertension Association's 2022 International Conference Scientific Sessions Overview

et al. 2023

View full text Add to dashboard Cite

The considerable progress made in recent years in the diagnosis, risk stratification, and treatment of pulmonary hypertension was highlighted during the most recent edition of the Pulmonary Hypertension Association Scientific Sessions, which was held in Atlanta, Georgia from June 9 to 11, 2022, with the theme: Vision for the PHuture: The Evolving Science and Management of PH. Content presented over the 3‐day conference focused on scientific and management updates since the last sessions were held in 2018 and included didactic talks, debates, and roundtable discussions across a broad spectrum of topics related to pulmonary hypertension. This article aims to summarize the key messages from each of the session talks.

show abstract

Impact of COVID-19 Pandemic on Care of Pulmonary Hypertension Patients

Cited by 2 publications

References 0 publications

Impact of the COVID‐19 pandemic on care disruptions, outcomes, and costs in patients receiving pulmonary arterial hypertension‐specific therapy in the United States of America: An observational study

Impact of the COVID‐19 pandemic on care disruptions, outcomes, and costs in patients receiving pulmonary arterial hypertension‐specific therapy in the United States of America: An observational study

Pulmonary Hypertension Association's 2022 International Conference Scientific Sessions Overview

Contact Info

Product

Resources

About